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Over the past 5 years, numerous state and local activities have targeted opioid prevention 
among Alaskans, particularly youth and young adults. While surveillance data exists for youth, 
no specific data exists for opioid behaviors and perceptions among Alaskan young adults.  
 
Researchers at the University of Alaska Anchorage Center for Behavioral Health Research and 
Services conducted surveys in 2016 and 2019 to gather information on awareness, opioid and 
heroin use, social and retail access, and risk perceptions. At each timepoint, Alaskans age 18-27 
were randomly selected and invited to participate. Response rates for the surveys were 10.4% 
and 12.8%, respectively. Survey data were weighted for gender and borough in order to 
represent Alaska’s population of young adults.  
 
Changes from 2016 to 2019:  
 Increase in seeing awareness messages about opioids  
 Increase in rating prescription opioid misuse and heroin use as problems in community. 
 Increase in perceived risk from misusing opioids or using heroin.  
 
Among those who had been prescribed opioids in the past three years:  
 Decrease in reported conversations with doctor of pharmacist when receiving 
prescription 
 The percentage who had leftover pills remained high. Of those, increase in bringing 
leftover pills to pharmacy or other permanent disposal site.  
 
Survey findings indicate success at disseminating opioid prevention messages in the community 
and promoting disposal of leftover opioids. Additionally, increasing perceived risk among young 
adults in Alaska may predict future reductions in opioid and heroin use behaviors. Findings 
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In September of 2015, the Substance Abuse and Mental Health Services Administration (SAMHSA) 
awarded the Partnerships for Success (PFS) grant to the State of Alaska Department of Health and Social 
Services (DHSS), Division of Behavioral Health (DBH). The PFS grant program was a five-year effort 
focused on preventing and reducing substance use and building prevention capacity at both the state 
and community levels. DHSS provided coordination for the project and facilitated the conduct of project 
activities by community-level coalitions. Additionally, DHSS contracted with the Center for Behavioral 
Health Research and Services (CBHRS) at the University of Alaska Anchorage (UAA) to conduct a 
comprehensive statewide evaluation of the PFS project.  
 
Using a data-informed prioritization process to narrow the substance abuse focus of the grant, the State 
Epidemiological Outcomes Workgroup chose two PFS priority areas: 1) non-medical use of prescription 
opioids among 12-25 year olds; and 2) heroin use among 18-25 year olds. Additional background as 
well as secondary data on related to prescription opioids and heroin in Alaska are described in the 
Partnerships for Success Evaluation Technical Report 1.1  
 
Partnerships for Success (PFS) Approach and Funded Boroughs 
 
Through a competitive application process, six community coalitions, each representing an Alaska 
borough, received funding in July of 2016. The six funded boroughs (five urban and one rural) are 
presented in Table 1 and together comprise approximately 81% of Alaska’s total population according to 
the 2017 census estimates.2 
 
Table 1. Population of PFS Boroughs in Alaska 
 
 State Anchorage 
Fairbanks 







Population 737,080 297,483 97,738 32,269 58,024 104,166 8,748 
 
In each borough, community coalitions directed a variety of opioid prevention activities over the five-
year grant period. These activities included media campaigns, educational outreach and training 
activities for community members, safe storage and disposal resource distribution, and policy and 




The ability to monitor change in the non-medical use of prescription opioids and heroin use over the 
five-year grant project is important for performance measurement. However, no surveillance data is 
available for the specific priority areas of non-medical use of prescription opioids and heroin use, 
particularly among 18-25 year olds in PFS boroughs. In response to this data gap, a surveillance survey to 
assess non-medical use of prescription opioids and heroin use among 18-25 year olds was developed 
and administered in 2016 and repeated in 2019. These two data collection timepoints, one early in the 
PFS implementation and one near the end of the project, allow for pre-post analyses to assess change. 
 
In addition to measuring prescription opioid misuse and heroin use, the survey provided an opportunity 
to measure intervening variables of focus for the Alaska PFS project which include: 1) social access to 
prescription opioids through friends and family; 2) retail access to prescription opioids through providers 
and dispensers; and 3) perceived risk of harm from non-medical use of prescription opioids and heroin 





and follow-up. At baseline, the findings supported local-level understanding of each intervening variable 
and informed the selection of appropriate strategies. Follow-up findings both assessed change and 










Table 2 outlines the domains of the survey instrument. To develop the survey instrument, evaluators at 
CBHRS reviewed existing surveillance surveys and utilized similar items when possible. For example, 
consumption, perceived risk of harm, and ease of access items parallel items from SAMHSA’s National 
Survey on Drug Use and Health.3 Consistency of questions allows for the comparison of results between 
PFS boroughs, overall state estimates, and national estimates over time. Additional questions were 
developed by CBHRS evaluators to meet the specific needs of the project.  
 





Perceived extent of the problem in the community √ √ 
Consumption, misuse, and/or use (lifetime, past year, 
past 30 days) 
√ √ 
Days misused opioids/used heroin in the past 30 daysa √ √ 
Perceived risk of harm from trying once or twice √ √ 
Perceived risk of harm from using weekly √ √ 
Difficulties experienced from substance use √ √ 
Awareness of prevention messages √  
Prescribed opioids (lifetime, past three years) √  
Disposal practicesb  √  
Provider discussionsb √  
Ease of access to substancea √ √ 
How substance was accessed for misusea √  
Reasons for misuse of substancea √  
Doctor shopping behaviora √  
Only asked if: (a) prescription opioids misused or heroin used in past 30 days; (b) received an opioid prescription in 




For baseline data collection in 2016, a list of names and mailing addresses of 18-25 year olds residing in 
Alaska was purchased from a reputable market research company in order to conduct a mail-based 
survey. To address challenges encountered at baseline (and described in PFS Evaluation Report 1), the 
sampling approach was changed for follow-up data collection.1 The age range was also slightly expanded 
from 18-25 years old to 18-27 years old in order to capture individuals who were within the target age 
range during PFS implementation. In 2019, a list of names and mailing addresses of 18-27 year old 
registered voters with residential addresses in PFS-funded boroughs was obtained from the Alaska 
Division of Elections. Since voter registration became automatic with Permanent Fund Dividend 
applications (unless an individual opts out of voter registration) in 2017, the registered voter list is 
among the best sources for sampling, with the voter list exceeding 85% of the population estimate.2 The 
sampling plan at both timepoints was derived based on the budget available and the estimated 
population of 18-25 year olds in each funded borough. With a goal of obtaining 1,500 completed surveys 





invite 7,472 individuals. In order to allow for some undeliverable mail due to old or incorrect addresses, 
7,500 individuals were randomly selected from the mailing lists. For borough-level analyses, 
oversampling was necessary in smaller boroughs to reach the threshold of 150 completed surveys. At 
baseline, the complete mailing list of all 18-25 year olds in Sitka included only 380 individuals so all were 
invited to take the survey and sample sizes in other boroughs were adjusted to make up the shortfall in 
total invitations. Table 3 presents sampling by borough and timepoint.  
 
Data Collection and Incentives 
 
Recruitment was identical at baseline and follow-up. After obtaining approvals from the UAA 
Institutional Review Board (IRB) and the Alaska Area IRB, up to three survey invitation letters were 
mailed to all randomly selected individuals, with mailings occurring approximately every two weeks. The 
first invitation letter invited potential participants to complete the survey online by providing a survey 
link, a unique passcode, and a small notebook as a pre-incentive. The second invitation letter contained 
the same online survey link and passcode but also included a paper survey and pre-addressed and pre-
paid return envelope. The last letter specified that it was the final request and again included the online 
survey link and unique passcode. Once individuals responded to the survey, no further invitation letters 
were sent. Once a unique passcode was used to complete the survey, it could not be used a second 
time, preventing duplicate responses and limiting unintended participation. Baseline data collection 
occurred from October 10th to November 28th, 2016 and follow-up data collection took place from 
September 13th to November 10th, 2019.  
 
Survey participants received a $15 gift certificate to a local grocery store and were entered into a 




At baseline, a total of 779 surveys were completed by eligible individuals within the target age range, 
resulting in a 10.4% response rate. At follow-up, 961 completed surveys were returned, resulting in a 
12.8% response rate. Although the goal sample size of 1,500 was not reached at either timepoint, power 
analyses indicated 99% certainty that sample estimates are within ± 4.6% of the population. Table 3 
outlines the survey response rate by borough and timepoint.  
 



















































Sample Demographics and Data Weighting 
 
Data weights were applied by borough size and gender to match census estimates of the target 
population in PFS boroughs (see Table 4). At each timepoint, the most recent available census 
population estimates were used to calculate weights; 2014 estimates were used for baseline weighting 
and 2017 estimates for follow-up weighting.1,4 At baseline, 13 respondents who did not identify as a 





other gender identities. At follow-up, gender information supplied by the Division of Elections was 
substituted in order to allow for weighting (n = 32).  
 
Gender and race characteristics of the survey sample before and after weighting are presented in Table 
4. These categories are used for data breakdowns in the remainder of the report. In the survey, 
respondents were asked to indicate all races with which they identify. To allow for an adequate sample 
size in each race group, responses are grouped into three categories that are used for race comparisons 
throughout the report: 1) White/Caucasian alone, non-Hispanic; 2) Alaska Native or American Indian 
alone or in combination with one or more other races; and 3) other race(s) alone or in combination.  
 




n = 766 
Follow-Up (2019) 












Men 263 34.3 54.2 345 35.9 52.7 




545 71.1 67.1 660 70.8 68.3 
Alaska Native/American Indian 
alone or in combination with 
one or more races 
105 13.7 14.3 128 13.7 13.0 
Other race(s) alone or in 
combination 







Findings: Prescription Opioids 
 
To gather information on participants’ use, consequences, and perceptions related to prescription 
opioids, the survey clearly defined prescription opioids as pain killers which include codeine, 
hydrocodone/Vicodin/Norco, oxycodone/OxyContin/Percocet, Meperidine/Demerol, 
fentanyl/Duragesic, hydromorphone/Dilaudid/Exalgo, morphine/Astramorph/Avinza, buprenorphine, 
Methadone, etc. Survey instructions also specified that prescription opioids do not include “over-the-
counter” pain relievers such as aspirin, Tylenol, Advil, or Aleve, or prescription dosages of these 
medications.  
 
Using the weighted sample as described previously, detailed survey results comparing baseline to 
follow-up are presented in the following pages. Demographic comparisons are displayed for gender and 
race when the sample size is adequate. 
 
Follow-up questions were asked only of respondents who reported prescription opioid misuse during 
the past 30 days. The group of respondents reporting past 30 day use and eligible for follow-up 
questions was smaller than expected at both timepoints (baseline: n = 5; follow-up: n = 5). As a result, 
findings from follow-up questions for this subgroup are not displayed. 
 
Awareness and Attitudes 
 
At both timepoints, participants reported whether they had seen various types of awareness messages 
about prescription opioids. More participants reported seeing awareness messages at follow-up 
compared to baseline, F(1, 1,673) = 12.65, p < .001, ƞ2 = .009. Participants most often reported seeing 
messages about safe use of opioids and safe disposal of opioids. The biggest increases in the types of 
messages seen from baseline to follow-up were for messages about safe disposal of prescription opioids 
and risks of sharing with others. See Figures 1 and 2. 
 
This pattern of seeing an increased number of awareness messages at follow-up was also observed 
across all demographic subgroups, with a significant effect for race such that more participants who 
identified as white reported seeing messages than those who identified as other, F(1, 1,673) = 4.94, p < 
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Figure 2. Some Type of Prescription Opioid Message Seen in Total and by Gender 
 
 
Figure 3. Some Type of Prescription Opioid Message Seen by Race 
 
 
Participants were asked to rate the severity of the prescription opioid misuse problem in their 
community, using a scale from 1 (“no problem at all”) to 6 (“a very large problem”). Participants rated 
prescription opioid misuse as significantly more of a problem at follow-up (M = 4.4; SD = 1.5) compared 
to baseline (M = 3.6, SD = 1.6), F(1, 1,643) = 53.77, p < .001, ƞ2 = .032. See Figure 4.  
 
Additionally, ratings of prescription opioid misuse as a problem in the community were higher among 
participants who identified as female (M = 4.2, SD = 1.6) compared to those who identified as male (M = 

















































Figure 4. Perceived Severity of Prescription Opioid Misuse as a Problem in the Community  
in Total and by Gender 
 
 
Figure 5. Perceived Severity of Prescription Opioid Misuse as a Problem in the Community by Race 
 
 
Retail Access to Prescription Opioids 
 
Retail access is the ability to obtain prescription opioids for misuse through a provider or dispenser. At 
both timepoints participants reported whether they had ever been prescribed opioids during their life. 
They also reported when they had been prescribed opioids, specifically whether it was within the last 
three years or more than three years ago. Overall, more participants reported being prescribed opioids 
































significant. This increasing trend was also observed among male respondents but little difference 
between timepoints for female participants. (See Figure 6.) A greater percentage of respondents who 
identified as White (56.6%) or Alaska Native/American Indian (54.5%) reported receiving at least one 
lifetime opioid prescription as compared to respondents of another race (38.4%), F(1, 1,643) = 12.47, p < 
.001, ƞ2 = .015, as shown in Figure 7.  
 
Figure 6. Prescribed Opioids Lifetime in Total and by Gender 
 
 


















































Gender and race differences diminish when comparing respondents who received an opioid prescription 
in the past three years versus anytime in their life. See Figures 8-11. 
 
Figure 8. Prescribed Opioids in the Past 3 Years in Total and by Gender 
 
 
















































Figure 10. Prescribed Opioids More than 3 Years ago in Total and by Gender 
 
 
Figure 11. Prescribed Opioids More than 3 Years ago by Race 
 
 
At both timepoints respondents who were prescribed opioids in the past three years were asked if they 
had engaged in any type of conversation with their doctor or pharmacist when receiving a prescription. 
Most participants (84.4% at baseline and 77.8% at follow-up) reported having some type of conversation 
with their provider; the reduction from baseline to follow-up is not statistically significant. Respondents 
were asked which specific topic(s) they discussed with their doctor or pharmacist when receiving a 
prescription (see Figure 12). At both timepoints, fewer than a quarter of respondents reported talking 
with their provider about alternative medications to opioids or the potential risk of developing an opioid 















































fewer reported those conversations at follow-up. The most common topic discussed with a doctor or 
pharmacist was the side effects of using prescription opioids; this conversation also was reported less 
frequently at follow-up compared to baseline.  
 
Few respondents reported that their physician or pharmacist addressed social access considerations 
with them when prescribing or dispensing opioids in the past three years. At both timepoints, fewer 
than a third of participants reported their physician or pharmacist talked to them about not sharing their 
medication. Additionally, the percentage of participants who reported a conversation advising them to 
store their prescription in a safe and secure location decreased from 27.0% at baseline to 17.8% at 
follow-up. See Figure 12. 
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Social Access to Prescription Opioids 
 
Social access is the ability to obtain prescription opioids through friends and family without a 
prescription and includes getting pills for free, paying for pills, and stealing pills from friends and family. 
Previous research has found that friends, family, and other acquaintances are the most common source 
of prescription opioids for misuse.5,6 Only very few individuals indicated that they had misused 
prescriptions opioids within the past 30 days (0.7% at baseline and 0.5% at follow-up). Therefore, the 
current surveys have little ability to determine how pills are acquired among this group but other data 
are available that provide this information. NSDUH data from 2011-2014 indicate that 66.8% of 
individuals ages 12-25 who misused prescription opioids during the past year in Alaska reported to get 
them through a friend or relative, while only 19.6% received them directly from a doctor. This finding 
demonstrates that social access is a primary source of prescription opioid acquisition among youth and 
young adults in Alaska.7  
 
In the young adult surveys, the majority of individuals who received a prescription for opioids in the past 
three years had pills leftover (71.8% at baseline, 79.1% at follow-up), indicating it may be common for 
prescriptions to include more pills than necessary. This creates a potential opportunity for others to 
access prescription opioids through social sources. While the percentage of respondents who had pills 
leftover from their last prescription increased over time, the difference approached significance but was 
not significant, X2(1, n = 437) = 3.60, p = .058. Therefore, the potential for social access via leftover pills 
remained rather high and consistent over time.  
 

































Among the respondents who had pills leftover there was no significant change from baseline to follow-
up in the percentage of respondents who reported disposing of leftover opioids, although there was a 
significant increase in those who specifically reported bringing their leftover opioids to a pharmacy or 
other permanent drug disposal site, X2(1, n = 448) = 22.09, p < .001. See Figure 15.  
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Prescription Opioid Misuse 
 
Prescription opioid misuse was defined in the survey as use without a doctor’s prescription or in a way 
that a doctor has not directed. Misuse includes using a prescription opioid: 1) without a valid 
prescription; 2) in greater amounts, more often, or longer than directed; or 3) in any other way than as 
directed by a doctor. At both timepoints participants were asked to report if they had misused opioids 
and indicate when (i.e., in the past 30 days; more than 30 days, but within the past year; or more than a 
year ago). Given that only a small percentage of survey respondents reported misusing opioids in the 
past 30 days (0.7% at baseline; 0.5% at follow-up), there was not enough data to allow for meaningful 
comparisons by gender and race. Additionally, only a small percentage of respondents reported past 
year opioid misuse (2.5% at baseline; 2.3% at follow-up); therefore, the sample size was not adequate 
for comparisons by demographics for any recent misuse.  
 
Past year estimates of misuse from baseline (2.5%) and follow-up (2.3%) surveys are both considerably 
lower than NSDUH prevalence estimates of past year non-medical use of prescription pain relievers 
among 18-25 year olds in Alaska, which was 9.0% in 2013-20148 and 6.3% in 2017-2018.9  
 
A total of 9.6% of respondents at baseline and 12.3% at follow-up (see Figure 16) reported prescription 
opioid misuse at least once in their lifetime. At both timepoints a greater percentage of participants who 
identified as White (12.6%) reported lifetime prescription opioid misuse than those who identified as 
Alaska Native/American Indian (7.0%) or another race (7.6%), F(1, 1,663) = 4.39, p < .001, ƞ2 = .010. See 
Figure 17. There were no significant differences observed between male and female respondents.  
 























Figure 17. Lifetime Misuse of Prescription Opioids by Race 
 
 
Perceived Risk of Harm from Prescription Opioid Misuse 
 
Perceived risk of harm was defined in the survey as the likelihood of physical risk or other harms from 
misusing prescription opioids. On a scale from 1 (“no risk”) to 6 (“great risk”), respondents were asked 
to rate their perception of risk of harm from two different types of prescription opioid misuse - misuse 
once or twice and regular misuse. Overall, ratings of perceptions of risk increased from baseline to 
follow-up. Specifically, participants’ ratings of risk from prescription opioid misuse once or twice 
increased significantly from baseline (M = 4.2, SD = 1.6) to follow-up (M = 4.7, SD = 1.5), F(1, 1,660) = 
14.93, p < .001, ƞ2 = .009. See Figure 18. Additionally, perceptions of risk pertaining to regular 
prescription opioid misuse also increased significantly from baseline (M = 5.1, SD = 1.4) to follow-up (M 
= 5.4, SD = 1.1), F(1, 1,660) = 17.36, p < .001, ƞ2 = .010. See Figure 20.  
 
Among gender subgroups, results indicate that female respondents perceived more risk from opioids 
than males, both in trying opioids once or twice, females: M = 4.6, SD = 1.5 vs males: M = 4.4, SD = 1.6, 
F(1, 1,660) = 8.39, p < .01, ƞ2 = .005, and from regular prescription opioid misuse, females: M = 5.3, SD = 
1.2 vs males: M = 5.2, SD = 1.3, F(1, 1,660) = 5.61, p = .02, ƞ2 = .003. See Figures 18 and 20. 
 
Among racial subgroups, respondents who identified as White (M = 5.4, SD = 1.1) rated regular opioid 
misuse as a higher risk for causing individual harm than those who identified as Alaska Native/American 
Indian (M = 4.9, SD = 1.7) or another race (M = 5.0, SD = 1.5), F(1, 1,660) = 19.17, p < .001, ƞ2 = .023. See 






















Figure 18. Perceived Risk of Harm from Misusing Prescription Opioids Once or Twice  
in Total and by Gender 
 
 



































Figure 20. Perceived Risk of Harm from Regular Prescription Opioid Misuse in Total and by Gender 
 
 



































Difficulties Related to Prescription Opioid Misuse 
 
At both timepoints respondents were asked if they had experienced any difficulties related to opioid 
misuse. Significantly more participants reported one or more difficulty at baseline (3.3%) compared to 
follow-up (1.7%), X2(1, n = 1,727) = 4.70, p = .03. Difficulties were reported by participants who did not 
report opioid misuse, indicating that the question captured difficulties experienced by family members, 
partners, and friends of individuals who misuse opioids. Consistent with the trend among the overall 
sample, among respondents who reported misusing opioids in the past 12 months, more participants at 
baseline (47.4%) compared to follow-up (4.5%) reported at least one difficulty, X2(1, n = 41) = 10.14, p < 
.01. At both timepoints the most common difficulties reported were “concerns about personal safety,” 








To gather information on participants’ use, consequences, and perceptions related to heroin, the survey 
explained that heroin can be smoked or injected and can be purchased in a variety of forms and colors. 
Heroin was described to survey respondents as simply heroin; no other street names or descriptions 
were provided. Using the weighted sample as described previously, detailed survey results comparing 
baseline to follow-up are presented in the following pages. Demographic comparisons are displayed for 
gender and race when the sample size is adequate. Follow-up questions were asked of respondents who 
reported heroin during the past 30 days; however, this group was smaller than expected at 




At both timepoints, participants were asked to rate the severity of heroin use as a problem in their 
community, using a scale from 1 (“no problem at all”) to 6 (“a very large problem”). Overall, participants 
rated heroin use as more of a problem at follow-up (M = 4.4; SD = 1.6) compared to baseline (M = 3.8; 
SD = 1.8), F(1, 1,654) = 23.76, p < .001, ƞ2 = .014. See Figure 22. Additionally, participants who identified 
as female, on average, rated the severity of the heroin problem as higher than those who identified as 
male, F(1, 1,654) = 13.90, p < .001, ƞ2 = .008. 
 





At both timepoints participants were asked to report if they had used heroin and indicate when (i.e., in 
the past 30 days; more than 30 days, but within the past year; or more than a year ago). Only a very 
small number of survey respondents reported misusing heroin in the past 30 days (baseline: n = 3; 
follow-up: n = 2) or past year (baseline: n = 5; follow-up: n = 3); therefore, there was not an adequate 




















Past year estimates from both surveys were similar to other NSDUH prevalence estimates among 18-25 
year olds in Alaska during 2017-2018 (0.65%)9 and national prevalence estimates in 2017-2018 
(0.54%).10 
 
A total of 2.7% of respondents at baseline and 2.8% at follow-up (see Figure 23) reported using heroin at 
least once in their lifetime. There were no significant differences observed for gender or race subgroups. 
 
A smaller number of survey respondents reported lifetime heroin use (2.7% at baseline, 2.8% at follow-
up) compared to prescription opioid misuse (9.7% at baseline, 12.3% at follow-up) but a relationship in 
use exists between these two substances. Research suggests that non-medical use of prescription 
opioids is a strong risk factor for later initiation of heroin use and a large percentage of current heroin 
users begin their abuse of opioids with prescription opioids.5,11,12,13 Similar to the pattern identified in 
research findings, 78.7% of lifetime heroin users from the combined baseline and follow-up unweighted 
survey sample (n = 37 out of 47) reported lifetime prescription opioid misuse but only 18.3% of lifetime 
prescription opioid misusers (n = 37 out of 202) reported lifetime heroin use. However, the sequential 
order of substance abuse initiation among this sample cannot be determined due to the cross-sectional 
nature of the survey data. 
 
Figure 23. Lifetime Use of Heroin in Total and by Gender 
 
 
Perceived Risk of Harm from Heroin Use 
 
Perceived risk of harm was defined in the survey as the likelihood of physical risk or other harms from 
using heroin. On a scale from 1 (“no risk”) to 6 (“great risk”), respondents were asked to rate their 
perceptions of risk of harm from two different types of heroin - use once or twice and regular misuse. 
Overall, results suggest that ratings of perceptions of risk increased from baseline to follow-up. 
Specifically, participants ratings of risk pertaining to individual harm from heroin use once or twice 
increased significantly from baseline (M = 5.1, SD = 1.4) to follow-up (M = 5.4, SD = 1.2), F(1, 1,660) = 
8.74, p < .01, ƞ2 = .005). See Figure 24. Additionally, perceptions of risk pertaining to regular heroin use 
also increased significantly from baseline (M = 5.5, SD = 1.2) to follow-up (M = 5.7, SD = 0.9), F(1, 1,660) 



















Among gender subgroups, results indicate that female respondents perceived more risk of individual 
harm from heroin use than males, both in trying heroin once or twice, females: M = 5.4 and SD = 1.1 vs 
males: M = 5.2, SD = 1.4, F(1, 1,660) = 22.75, p < .001, ƞ2 = .014, and from regular heroin use, females: M 
= 5.7 and SD = 1.0 vs males: M = 5.5, SD = 1.2, F(1, 1,660) = 9.60, p < .01, ƞ2 = .006. See Figures 24 and 
26. 
 
Among racial subgroups, respondents who identified as White (M = 5.3, SD = 1.2) rated regular heroin 
use as a higher risk for causing individual harm than those who identified as Alaska Native/American 
Indian (M = 5.0, SD = 1.6) or another race (M = 5.1, SD = 1.4), F(1, 1,660) = 21.56, p < .001, ƞ2 = .025. See 
Figure 27.  
 




















Figure 25. Perceived Risk of Harm from Using Heroin Once or Twice by Race 
 
 

































Figure 27. Perceived Risk of Harm from Regular Heroin Use by Race 
 
 
Difficulties Related to Heroin Use 
 
At both timepoints respondents were asked if they had experienced any difficulties related to heroin 
use. Roughly the same percentage of participants reported one or more difficulty at baseline (2.1%) and 
follow-up (2.3%). Among respondents who reported using heroin in the past 12 months, all reported 
experiencing at least one difficulty related to their heroin use. There were also participants who did not 
report heroin use that reported difficulties (baseline: n = 19, follow-up: n = 14), suggesting that the 
question may have captured difficulties experienced by family members, friends, or partners of 
individuals who used heroin. The most commonly reported difficulties at both timepoints were 
“relationship difficulties,” “craving the substance a lot,” “trouble keeping up with family 





















Prescription opioid misuse and heroin use are public health concerns in both Alaska and the nation and 
are best addressed using data-informed decision making and evidence-informed approaches.6 The two 
surveys described in this report represent just one component of a comprehensive mixed-method 
evaluation conducted by CBHRS evaluators for the five-year PFS project which targets the prevention of 
prescription opioid misuse among 12-25 year olds and heroin use among 18-25 year olds. These surveys 
of young adults fill a critical data gap and increase understanding of opioid and heroin behaviors and 
perceptions among Alaskan young adults.  
 
Over the five years of the PFS project, coalitions organized and implemented numerous prevention 
activities in their communities. Concurrently, the opioid epidemic has received large amounts of state 
and national attention, including media coverage and policy changes, such as declaration of a public 
health emergency by Alaska’s governor in 2017. While the methodologies used in this survey effort do 
not allow us to elucidate the relative influence of any specific activity or action on changes observed 
over time, we can summarize the overall status of Alaskan young adults in 2016 and 2019 and describe 




No differences over time occurred in opioid misuse or heroin use behaviors. Change was documented in 
other indicators, however, including cognitions and perceptions that are associated with substance 
behaviors and in experiences with prescriptions. 
 
Awareness 
Awareness of the target issue is a critical component for prevention. More participants reported seeing 
opioid awareness messages in 2019 compared to 2016. This increase follows PFS coalitions working to 
implement media campaigns as well as other awareness activities in their communities and the increase 
suggests success in disseminating the prevention messages. Nonetheless, 40% of respondents in 2019 
did not report seeing messages and participants who identified as White or Alaska Native/American 
Indian were more likely to have seen messages than participants of other races. Opportunities persist 




Individuals who perceive greater risk associated with use of substances are less likely to engage in use 
behaviors.14 Therefore, prevention efforts can target perceptions with the goal of increasing individuals’ 
perceptions of risk. From 2016 to 2019, Alaskan young adults’ perceptions of risk associated both with 
opioid misuse and heroin use increased significantly. While reported use did not change, risk 
perceptions can serve as an early indicator and, in this case, may predict future reductions in opioid and 
heroin use behaviors. Greater perceived risk was reported by female participants (compared to male 
participants) and participants who identified as White (compared to those who identified as Alaska 
Native/American Indian or another race). This pattern of demographic differences in risk perceptions is 
similar to results observed in the Alaska YRBS statewide survey, suggesting that differences in risk 
perceptions between adolescent groups may persist into young adulthood.15 Additionally, gender 
differences have been well-documented in the literature for general risk perceptions, as well as for 
specific substances.16,17,18 Recent young adult opioid risk perception research in other locales also 





differences present opportunities for prevention efforts to target risk perceptions among specific 
subgroups for increased impact.  
 
Opioid Prescriptions  
Among those participants who had been prescribed opioids within the past three years, fewer 
participants in 2019 compared to 2016 reported having had conversations with healthcare providers 
when receiving the prescription. Specifically, fewer respondents reported conversations about safe 
storage of the medication and about using the medication as prescribed and not more. Other important 
conversations were reported consistently over time but relatively infrequently, with less than a third of 
respondents reporting conversations about not sharing opioids and less than a quarter recalling 
discussions about risk of opioid use disorder. While providers may, in fact, be covering these topics more 
frequently than participants recall, the findings support the need for improved communication. Patient 
education can take many forms and providers, dispensers, and their organizations might work together 
to provide specific information to patients via multiple methods. General education for the public can 
also continue to be supported by local prevention groups and state agencies, such as with broad media 
campaigns.  
 
The proportion of patients receiving opioid prescriptions who reported having leftover medication 
remained high from 2016 to 2019, creating a potential opportunity for opioids to be available to others 
via social access. Among those same individuals, reports of disposal of leftover medication at 
pharmacies or other permanent disposal sites increased in 2019, reflecting improved feasibility of that 
strategy for reducing social access. Opportunities persist for increasing awareness of the importance of 
disposal as well as promoting feasible disposal options, which may include providing individual disposal 
bags with prescriptions as well as promotion of permanent disposal sites.  
 
Limitations 
The findings reported here reflect data collected through two survey administrations. Participants were 
randomly selected from publicly-available sources of names and contact information. However, these 
sources were not exhaustive and did not include all residents who met inclusion criteria. Additionally, 
we invited participants via mail and may have missed individuals who moved during the recruitment 
period.  
 
While we weighted data to approximate the state’s population in geography and gender, our sample 
differed from other surveillance data on opioid misuse and heroin use behaviors, with substantially 
fewer of the survey participants reporting use behaviors, particularly within the past year. It is possible 
participants with current or former opioid use patterns were less likely to be willing to participate than 
other individuals and are therefore under-represented in our samples.  
 
Recommendations 
Despite the limitations, the findings presented here provide evidence documenting progress in opioid 
prevention among Alaskan young adults from 2016 to 2019 as well as support continued prevention 
efforts. Specific recommendations:  
- Distribute awareness messages broadly to Alaska communities in a variety of formats in order to 
reach diverse Alaskans  
- Target risk perceptions among youth and young adults, attempting to increase their perceptions 
of risk associated with opioid misuse and heroin use, particularly among males and non-White 
individuals.  
- Support general patient education and specific patient-provider communication related to risks 
associated with prescription opioids and how to use medication safely and promote safe storage 
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